Cost-effectiveness of daclatasvir plus asunaprevir for chronic hepatitis C genotype 1b treatment-naïve patients in China.
BACKGROUND:Hepatitis C is the second fastest growing infectious disease in China. The standard-of-care for chronic hepatitis C in China is Pegylated interferon plus ribavirin (PR), which is associated with tolerability and efficacy issues. An interferon- and ribavirin-free, all-oral regimen comprisi...
Na minha lista:
| Principais autores: | , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Public Library of Science (PLoS)
2018-01-01
|
| coleção: | PLoS ONE |
| Acesso em linha: | http://europepmc.org/articles/PMC5892899?pdf=render |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|